Key facts
- AecorBio’s last known valuation is $30.0M (Sep 2025).
- It has raised $1.5M across 1 recorded rounds; the latest was Seed Round ($2.5M) in Aug 2025.
- AecorBio has filed 1 Form D with the SEC, most recently Nov 2025 ($2.5M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for AecorBio
Funding rounds
1 roundsAbout AecorBio
Developer of bioactive peptide therapeutics designed to address treatment resistance. The company's platform uses AI-driven peptide design, high-throughput protein hydrolysis, and cellular assays to identify peptides that reverse gene expression changes associated with disease resistance, enabling oncology, inflammatory, and autoimmune therapy markets to develop treatments that restore cellular microenvironments, reactivate immune responses, and improve patient outcomes by targeting the root causes of therapeutic failure with precision and scalability.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
AecorBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AecorBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AecorBio in its N-PORT filings yet. We sweep new filings monthly.